The FDA on Tuesday approved...

...Johnson & Johnson's IL-23 inhibitor Tremfya for the treatment of psoriatic arthritis. The drug will have to face off against immunology powerhouses Humira, Otzela and Enbrel, but it may be able to forge its own path as the first IL-23 inhibitor in the market basket. Tremfya is currently approved for the treatment of psoriasis, and holds preferred status under the pharmacy benefit for 33% of covered lives, with prior authorization and/or step therapy. 1% of covered lives have preferred access to Tremfya without any utilization management restrictions.

SOURCE: MMIT Analytics, as of 7/15/20